CA2022610A1 - Proteine gp130 humaine - Google Patents

Proteine gp130 humaine

Info

Publication number
CA2022610A1
CA2022610A1 CA2022610A CA2022610A CA2022610A1 CA 2022610 A1 CA2022610 A1 CA 2022610A1 CA 2022610 A CA2022610 A CA 2022610A CA 2022610 A CA2022610 A CA 2022610A CA 2022610 A1 CA2022610 A1 CA 2022610A1
Authority
CA
Canada
Prior art keywords
protein
human
interleukin
receptor
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2022610A
Other languages
English (en)
Other versions
CA2022610C (fr
Inventor
Tadamitsu Kishimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2022610A1 publication Critical patent/CA2022610A1/fr
Application granted granted Critical
Publication of CA2022610C publication Critical patent/CA2022610C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002022610A 1989-08-03 1990-08-02 Proteine gp130 humaine Expired - Lifetime CA2022610C (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP20023089 1989-08-03
JP01-200230 1989-08-03
JP2140069A JP2898064B2 (ja) 1989-08-03 1990-05-31 ヒトｇｐ１３０蛋白質
JP02-140069 1990-05-31

Publications (2)

Publication Number Publication Date
CA2022610A1 true CA2022610A1 (fr) 1991-02-04
CA2022610C CA2022610C (fr) 2001-01-30

Family

ID=26472699

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002022610A Expired - Lifetime CA2022610C (fr) 1989-08-03 1990-08-02 Proteine gp130 humaine

Country Status (10)

Country Link
US (1) US5132403A (fr)
EP (1) EP0411946B1 (fr)
JP (1) JP2898064B2 (fr)
KR (1) KR0178384B1 (fr)
AT (1) ATE147099T1 (fr)
AU (1) AU635296B2 (fr)
CA (1) CA2022610C (fr)
DE (1) DE69029545T2 (fr)
ES (1) ES2096580T3 (fr)
IL (1) IL95235A (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
AU3233193A (en) * 1991-12-18 1993-07-19 Icu Medical, Inc. Medical valve
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
US5891998A (en) * 1993-06-23 1999-04-06 Istituto Di Ricerche Di Biologica Molecolare P. Angeletti S.P.A. Interleukin-6 receptor agonists
IT1261787B (it) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
WO1996000462A1 (fr) * 1994-06-23 1996-01-04 Elin Motoren Gesellschaft M.B.H Systeme de refroidissement pour moteur
GB9419021D0 (en) * 1994-09-21 1994-11-09 Applied Research Systems Therapeutic protein
ATE552012T1 (de) 1994-10-07 2012-04-15 Chugai Pharmaceutical Co Ltd Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff
JP3458512B2 (ja) 1995-02-23 2003-10-20 東ソー株式会社 骨密度の変動推定方法又は骨そしょう症の診断方法及びこれに用いる試薬キット
US5674995A (en) * 1995-06-07 1997-10-07 Gen-Probe Incorporated Oligonucleotides specific for cytokine signal transducer gp130 mRNA
KR19990022359A (ko) * 1995-06-07 1999-03-25 다니엘 엘. 캐시앙, 헨리 엘. 노르호프 시토킨 시그날 트랜스듀서 ｇｐ130 ｍＲＮＡ에 특이적인 올리고뉴클레오티드
US5747470A (en) * 1995-06-07 1998-05-05 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
CA2237114A1 (fr) * 1995-11-07 1997-05-15 Kaneka Corporation Autoantigenes
ATE547119T1 (de) 1997-03-21 2012-03-15 Chugai Pharmaceutical Co Ltd Präventives oder therapeutisches mittel mit einem il-6-antagonisten als wirkstoff für durch sensibilisierte t-zellen vermittelte erkrankungen
EP1188830B1 (fr) 1999-06-02 2010-01-20 Chugai Seiyaku Kabushiki Kaisha Proteine receptrice d'hemopoietine
WO2001016166A2 (fr) * 1999-08-27 2001-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polypeptides comprenant des domaines de recepteur d'interleukine-6 se liant a un ligand, acides nucleiques correspondants, anticorps, compositions, et leurs procedes d'utilisation
ES2254224T3 (es) 1999-09-27 2006-06-16 Chugai Seiyaku Kabushiki Kaisha Nueva proteina del receptor de hematopoyetina, nr12.
US7175988B2 (en) * 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
GB0210539D0 (en) * 2002-05-08 2002-06-19 Univ Edinburgh Control of es cell self renewal and lineage specification, and medium therefor
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
RU2446826C2 (ru) 2005-10-14 2012-04-10 Фукуока Юниверсити Агенты для подавления повреждения трансплантированных островков после трансплантации островков
JP4837358B2 (ja) * 2005-10-19 2011-12-14 株式会社野村工電社 ボトル飲用水充填装置
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
AR057941A1 (es) 2005-11-25 2007-12-26 Univ Keio Agentes terapeuticos para el cancer de prostata
JP5033643B2 (ja) 2006-01-27 2012-09-26 学校法人慶應義塾 脈絡膜血管新生を伴う疾患の治療剤
CA2648644C (fr) 2006-04-07 2016-01-05 Osaka University Promoteur de regeneration musculaire
BRPI0712426B1 (pt) 2006-06-08 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Usos de um anticorpo anti-nr10/il-31ra com atividade neutralizante de nr10/il-31ra, de um fragmento e/ou um fragmento quimicamente modificado do anticorpo e de um agente
CA2666599A1 (fr) 2006-08-18 2008-02-21 Ablynx N.V. Sequences d'acides amines dirigees contre l'il-6r et polypeptides les contenant utilises pour le traitement de maladies et de troubles associes au signal medie par il-6
RU2450829C2 (ru) 2007-01-23 2012-05-20 Синсу Юниверсити Ингибитор хронического отторжения
US20080283557A1 (en) * 2007-05-17 2008-11-20 Julianne Desautels Spout for food stuff container
RU2596397C2 (ru) 2007-12-05 2016-09-10 Чугаи Сейяку Кабусики Кайся Терапевтическое средство от зуда
CN102256623A (zh) 2008-06-05 2011-11-23 独立行政法人国立癌症研究中心 神经浸润抑制剂
EP2226633A1 (fr) 2009-03-06 2010-09-08 Charité - Universitätsmedizin Berlin Utilisations et procédés d'identification d'un composé cytoprotecteur impliquant gp130 ou LIFRalpha
AU2010233658B2 (en) 2009-04-10 2013-11-28 Ablynx Nv Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
US10618964B2 (en) 2009-04-10 2020-04-14 Ablynx N.V. Nanobody against IL-6R
US20130149302A1 (en) 2010-05-28 2013-06-13 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for pancreatic cancer
PL2578231T3 (pl) 2010-05-28 2023-01-16 Chugai Seiyaku Kabushiki Kaisha Środek wzmacniający przeciwnowotworową odpowiedź limfocytów t
US10138302B2 (en) 2011-09-23 2018-11-27 Ablynx N.V. Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies
JP6442404B2 (ja) 2013-06-11 2018-12-19 国立研究開発法人国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
WO2016062766A1 (fr) 2014-10-21 2016-04-28 Ablynx Nv Traitement de maladies associées à il-6r
KR20180095740A (ko) 2015-02-27 2018-08-27 추가이 세이야쿠 가부시키가이샤 Il-6 관련 질환 치료용 조성물
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
EP3747469A4 (fr) 2018-01-31 2022-03-23 Motokazu Kato Agent thérapeutique pour l'asthme contenant un inhibiteur d'il-6
JPWO2020213665A1 (fr) 2019-04-17 2020-10-22
JP6845973B1 (ja) 2019-11-20 2021-03-24 中外製薬株式会社 抗体含有製剤
KR102351174B1 (ko) * 2020-05-11 2022-01-14 (주)아이테오솔루션즈 랜 포트의 혼동을 방지하는 어댑터 및 이를 포함하는 랜 포트 보안 장치
US11897951B2 (en) 2020-12-18 2024-02-13 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α

Also Published As

Publication number Publication date
KR0178384B1 (ko) 1999-04-01
AU635296B2 (en) 1993-03-18
DE69029545D1 (de) 1997-02-13
CA2022610C (fr) 2001-01-30
JPH0429997A (ja) 1992-01-31
EP0411946A2 (fr) 1991-02-06
IL95235A0 (en) 1991-06-10
ATE147099T1 (de) 1997-01-15
AU6003990A (en) 1991-02-07
KR910004801A (ko) 1991-03-29
EP0411946B1 (fr) 1997-01-02
IL95235A (en) 1995-11-27
US5132403A (en) 1992-07-21
JP2898064B2 (ja) 1999-05-31
DE69029545T2 (de) 1997-07-24
ES2096580T3 (es) 1997-03-16
EP0411946A3 (en) 1992-02-12

Similar Documents

Publication Publication Date Title
CA2022610A1 (fr) Proteine gp130 humaine
YU187789A (en) Diethers, which can be used at preparing zieglernatt's catalysts
CA2114015A1 (fr) Anticorps recombinants pour la therapie humaine
EP0853121A3 (fr) DNase humaine
CA2021528A1 (fr) Muteines de l'erythropoietine humaine, leur preparation et leur utilisation
WO1988003173A3 (fr) Nouvelles formes du facteur-1 de stimulation de colonies
AU7165287A (en) DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof
EP0219106A3 (fr) Polypeptides induisant des anticorps contre le virus du SIDA
IL66920A0 (en) Dna's,recombinant dna's,hosts containing them,polypeptides and their production
AU5072690A (en) Recombinant protein receptor
AU553717B2 (en) Amino-acid modified polyallylamines
AU8209187A (en) Hybrid proteins
AU5309390A (en) Soluble interferon-gamma receptors and methods for their production
IE890577L (en) Expression of hiv binding proteins
AU2179688A (en) Recombinant eukaryotic cells production interleukin-2, process and vectors for their preparation and process for the preparation of interleukin-2
IL92685A0 (en) Dna encoding lymphokine/cytokine like proteins,cells transformed thereby and production of said proteins and antibodies against them
EP0276778A3 (fr) Expression à haut niveau de IL-1bêta soluble et mature dans E. coli et dérivés ayant une activité biologique modifiée
AU5627090A (en) A novel alpha-amylase-pullulanase enzyme, a dna sequence coding the same, a recombinant dna molecule and a recombinant clone expressing the enzyme
AU1164588A (en) Nucleotide analogs, their production and use
EP0237676A3 (fr) Toxine de ricine recombinante
AU2040688A (en) Chemically durable, high index, low density glasses
AU599133B2 (en) Novel substituted (4.2.0.)bicyclooctane derivatives with valuable therapeutic properties
AU2459188A (en) Anticoagulative protein pp4-x, and its preparation and use
EP0343132A3 (en) Methods and systems for producing hiv antigens
AU1072588A (en) Cycloalkane (1,2-c:4,3-c') dipyrazoles

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry